Crypthecodinium

Crypthecodinium: A Comprehensive Reference Article

1. Identity: Taxonomy, Nomenclature, and Natural Sources

1.1 Taxonomic Classification and Nomenclature

Crypthecodinium cohnii is a species of dinoflagellate microalgae. Crypthecodinium belongs to the class Dinophyceae, order Peridiniales, and family Crypthecodiniaceae. Crypthecodinium cohnii is one of the heterotrophic dinoflagellates that inhabit the marine environment.

The taxonomic history of this organism is complex. The species was originally described as Glenodinium cohnii Seligo, 1887, and passed through several unaccepted synonyms including Gymnodinium fucorum Kuster, 1908; Gyrodinium cohnii Schiller, 1933; Gyrodinium fucorum Kofoid & Swezy, 1921; and Crypthecodinium setense Biecheler, 1938. The currently accepted combination, Crypthecodinium cohnii (Seligo) Chatton, was formally published in 1952 in the Traité de Zoologie.

The genus Crypthecodinium (Dinophyceae) currently consists of only one broadly recognized species: C. cohnii, a heterotrophic marine dinoflagellate widely known for its ability to produce prolific amounts of DHA. However, previous studies have revealed morphological and genetic differences among Crypthecodinium cohnii-like strains, indicating the potential of undiscovered diversity within this dinoflagellate. Indeed, recent research has reported significant genetic distances and phylogenetic cladding that support inter-specific variations within Crypthecodiniaceae, including the description of a new species, Crypthecodinium croucheri sp. nov., which has different genome sizes, ribotypes, and amplification fragment length polymorphism profiles compared to C. cohnii.

The NCBI taxonomy database classifies Crypthecodinium cohnii within: cellular organisms → Eukaryota → Sar → Alveolata → Dinophyceae → Gonyaulacales → Crypthecodiniaceae → Crypthecodinium.

1.2 Natural Source and Ecology

Crypthecodinium cohnii is defined as a chloroplast-lacking heterotrophic marine dinoflagellate that can exist in swimming or cyst forms, with cysts containing higher lipid amounts. In the marine environment, Crypthecodinium cohnii is usually found in full salinity seawater and, as such, is adapted to growth in an environment with a high chloride concentration. Known strains have been isolated from diverse marine environments, including Puerto Rico and shoreline organic debris from Tolo Harbor, Hong Kong. It has been suggested that the global distribution of C. cohnii strains is aided by tides and currents on which they attach to the surface of seaweed fragments or other mediators.

1.3 Commercial Forms and Preparations

The heterotrophic Crypthecodinium cohnii is a major model for dinoflagellate cell biology and a major industrial producer of docosahexaenoic acid (DHA), a key nutraceutical and added pharmaceutical compound. The commercially produced oil derived from this organism is marketed under the trade name DHASCO® (DHA Single Cell Oil). DHASCO oil, a designer single-cell oil, is produced by the single-cell alga Crypthecodinium cohnii grown under tightly controlled fermentation conditions; the algal oil is extracted from the cells and refined, and the whole process meets current Good Manufacturing Practices for food products.

DHA is derived from the heterotrophic microalga Crypthecodinium cohnii in a controlled fermentation process, and the resulting triglyceride oil (DHASCO®) naturally contains 480–600 mg/g DHA, which may then undergo transesterification and purification.

The oil is incorporated into numerous consumer products. It is also available commercially in the form of a spray-dried preparation with a 2-year shelf-life. The U.S. Pharmacopeia's Food Chemicals Codex distinguishes three types of algae-based DHA corresponding to three different algal oils: schizochytrium, crypthecodinium, and ulkenia. Typical end-use forms include:

• Encapsulated oils (soft-gel dietary supplement capsules)
• Oil incorporated into liquid or powdered infant formula
• Oil incorporated into fortified foods (snack bars, beverages, dairy products)
• Spray-dried microalgal biomass for aquaculture feed

2. Historical and Scientific Discovery

Crypthecodinium cohnii has no documented history of traditional human use in the ethnobotanical or ethnopharmacological sense. As a marine microalgae invisible to the naked eye, it was not known to pre-modern cultures and has no recorded use in any traditional medicine system. Its significance is entirely a product of modern science and biotechnology.

The organism was first formally described scientifically under the basionym Glenodinium cohnii Seligo in 1887. Interest in its lipid content emerged decades later: marine dinoflagellates such as C. cohnii were recognized as a source of polyunsaturated fatty acids (PUFAs) as early as 1970. However, a method for culturing C. cohnii with the purpose of extracting oil was not known until the registration of patents 5,374,657 and 5,407,957 by Martek Biosciences in 1994 and 1995, respectively. The intent of the manufacturer was to include the oil in infant formulas, baby foods, and dietary supplements in capsule form or by parenteral administration.

In the United States, the first commercially available DHA-containing oil for infant formulas was DHA Single Cell Oil (DHASCO®), produced from the microalgae Crypthecodinium cohnii. Both DHA and ARA have been added to U.S. infant formulas since 2002. C. cohnii was the first alga approved by the U.S. Food and Drug Administration for DHA production.

3. Key Constituents and Active Compounds

3.1 Lipid Profile

Crypthecodinium cohnii is unique among heterotrophic marine dinoflagellates in that DHA is almost exclusively the only PUFA present in its lipid and can be as high as 65% of the total fatty acids. This compositional singularity is of great industrial significance: among the heterotrophic marine dinoflagellates, Crypthecodinium cohnii has been identified as a prolific producer of DHA, and the organism is extraordinary in that it produces no other PUFAs than DHA in its cell lipid in any significant amount, which makes the DHA purification process very attractive, particularly for pharmaceutical and nutraceutical applications.

Currently, the heterotrophic marine dinoflagellate Crypthecodinium cohnii is a good candidate due to its ability to produce high-quality DHA with less than 1% of other types of PUFAs and without any EPA content. The lipid content of C. cohnii can reach more than 50% of its dry cell weight (DCW), and the proportion of DHA in total fatty acids can be approximately 40–50%.

DHA is contained entirely within the cells and is distributed in both structural lipids (e.g., phospholipids) and storage lipids.

3.2 The Active Compound: Docosahexaenoic Acid (DHA)

The sole clinically relevant active compound derived from Crypthecodinium cohnii is docosahexaenoic acid (DHA; chemical name: (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; systematic name: C22:6n-3). Structurally, DHA is a carboxylic acid with a 22-carbon chain and six cis double bonds, with the first double bond located at the third carbon from the omega end.

DHA is the most abundant omega-3 fatty acid in the brain and retina. DHA comprises 40% of the polyunsaturated fatty acids in the brain and 60% of the PUFAs in the retina. Fifty percent of a neuronal plasma membrane is composed of DHA.

3.3 Biosynthesis in C. cohnii

This microalgae is exceptional in that it can accumulate a high fraction of DHA with trivial amounts of other PUFAs in cell lipids. DHA-producing C. cohnii is cultivated in media containing glucose as a sole carbon source, so the media compositions are very important to DHA accumulation. Some of these organisms can be grown heterotrophically on organic substrates without light, offering the possibility of greatly increasing microalgal cell concentration under controlled and monitored conditions, resulting in a very high quality product.

The absence of EPA alongside DHA is industrially important: fish-based DHA has obvious disadvantages, such as heavy metal contamination, the typical fishy smell, and the presence of eicosapentaenoic acid (EPA). Other organisms produce two or more PUFAs in their lipids, and the complexity of their lipid profile can limit the use of their oils in some food and pharmaceutical applications.

4. Mechanisms of Action

4.1 Structural and Membrane Roles

The neurodevelopmental and neuroprotective actions of DHA are mediated by mechanisms involving membrane- and metabolite-related signal transduction. A key characteristic in the membrane-mediated action of DHA results from the stimulated synthesis of neuronal phosphatidylserine (PS). The resulting DHA-PS-rich membrane domains facilitate the translocation and activation of kinases such as Raf-1, protein kinase C (PKC), and Akt. The activation of these signaling pathways promotes neuronal development and survival.

The role of DHA-phospholipids in regulating G-protein signaling is relevant in the context of studies with rhodopsin. It is clear that the visual pigment responds to the degree of unsaturation of the membrane lipids. DHA modulates the carrier-mediated transport of choline, glycine, and taurine, the function of delayed rectifier potassium channels, and the response of rhodopsin contained in the synaptic vesicles.

4.2 Bioactive Metabolites

DHA is also metabolized in neural tissues to bioactive mediators. Neuroprotectin D1, a docosatriene synthesized by the lipoxygenase activity, has an anti-inflammatory property, and elovanoids formed from DHA elongation products exhibit antioxidant effects in the retina. Synaptamide, an endocannabinoid-like lipid mediator synthesized from DHA in the brain, promotes neurogenesis and synaptogenesis and exerts anti-inflammatory effects.

DHA undergoes enzymatic conversion by 15-lipoxygenase (Alox 15) to form oxylipins including resolvins and neuroprotectins, which are powerful lipid mediators. DHA is a critical contributor to cell structure and function in the nervous system, and deficits in DHA abundance are associated with cognitive decline during aging and in neurodegenerative disease. Recent studies underscore the importance of DHA-derived neuroprotectin D1 (NPD1) in the homeostatic regulation of brain cell survival and repair involving neurotrophic, antiapoptotic, and anti-inflammatory signaling.

4.3 Anti-inflammatory and Cell Signaling Roles

Since first being identified in the brain by Klenk and Bongard in 1952, many neurophysiological functions have been identified for DHA, including mediating the regulation of cell-survival, neuroinflammation, neurogenesis, and participating in signal transduction, as well as a newly identified role in blood-brain barrier (BBB) permeability.

Synaptamide, an endocannabinoid-like lipid mediator synthesized from DHA in the brain, promotes neurogenesis and synaptogenesis and exerts anti-inflammatory effects. It binds to the GAIN domain of the GPR110 (ADGRF1) receptor, triggers the cAMP/protein kinase A (PKA) signaling pathway, and activates the cAMP-response element binding protein (CREB).

5. Scientific Evidence by Area of Use

5.1 Infant Neurodevelopment and Brain Health

Background and rationale: DHA, enhanced in phospholipids in the central nervous system and retina, is recognized to play multiple roles in brain health and diseases, such as Alzheimer's disease. DHA is rapidly accumulated in the brain during gestation and early infancy, and the DHA availability from maternal stores can affect the DHA incorporation into neural tissues. Some studies have found that appreciable amounts of DHA in the brain may serve nutraceutical and neuroprotective effects.

Experimental evidence in animals has demonstrated that the effect of essential fatty acid deficiency during early brain development is deleterious and permanent. The risk of neurodevelopmental disorder is highest in very-low-birth-weight babies. Babies born of low birth weight or prematurely tend to have AA and DHA deficits; because disorders of brain development can be permanent, proper provision should be made to protect the AA and DHA status of both term and preterm infants to ensure optimum conditions for the development of membrane-rich systems such as the brain, nervous, and vascular systems.

Clinical evidence — infant formula studies: DHA and arachidonic acid (ARA) are components of human breast milk and commonly added to infant formula. The first DHA-containing algal oil for infant formulas was DHASCO® produced from the microalgae Crypthecodinium cohnii.

A randomized controlled study compared infant formula containing DHASCO® (derived from C. cohnii) against a new DHASCO®-B (from Schizochytrium sp.) in term infants from day of life (DOL) 14 to DOL 120. Assessments included weight, length, weight/length ratio, head circumference, red blood cell (RBC) DHA and other fatty acids, metabolic panel, safety, and tolerance. The rate of mean daily weight gain at DOL 120 was not significantly different between the formulas (29.1 ± 5.92 grams/day versus 29.9 ± 7.40 grams/day for DHASCO® and DHASCO®-B respectively; equivalence demonstrated at p=0.553). There was no significant difference between formulas in actual weight gain over time at DOL 30, 60, 90, and 120, including by gender. Overall weight gains were equivalent between the two formula groups. Further, RBC DHA levels were bioequivalent, and there was no difference in infant tolerability or parent satisfaction.

An FDA-reviewed safety dossier covering multiple studies found that formulas providing 0%, 0.32%, 0.64%, or 0.96% algal DHA derived from C. cohnii, all supplemented with ARA from Mortierella alpina, showed that algal DHA up to 0.96% of total fatty acids was well tolerated and no adverse effects were noted on measured outcomes including tolerance, adverse events, growth, red blood cell concentrations of fatty acids, and visual measures.

A few studies specifically reported no adverse effects of algal DHA from C. cohnii in both preterm and term infants (Columbo et al., 2011; Drover et al., 2011; 2012).

Evidence strength: The evidence that DHA from C. cohnii-derived oil is safe and well-tolerated in term and preterm infants is supported by multiple clinical trials and safety reviews conducted in the context of regulatory submissions. Evidence for specific neurodevelopmental outcomes attributable specifically to Crypthecodinium-sourced DHA (as distinct from DHA generically) is not well delineated in the published clinical literature; most neurodevelopmental benefits are attributed to DHA as a nutrient class rather than to the algal source specifically.

5.2 Bioavailability and Dose-Response in Adults

Arterburn et al. evaluated the bioavailability of DHA oils in capsules from two different algae (Crypthecodinium cohnii and Schizochytrium sp.) and found a dose-dependent response with doses from 200 to 1000 mg/day after 4 weeks. DHA response was dose-dependent and linear over the dose range; plasma phospholipid DHA increased by 1.17, 2.28 and 3.03 g per 100 g fatty acid at 200, 600, and 1,000 mg dose, respectively. Adverse event monitoring revealed an excellent safety and tolerability profile, and two different algal oil capsule supplements and an algal oil-fortified food represented bioequivalent and safe sources of DHA.

5.3 Neuroprotection, Cognitive Aging, and Neurodegeneration

Evolving research indicates that NPD1 has important determinant and regulatory interactions with the molecular-genetic mechanisms affecting β-amyloid precursor protein (βAPP) and amyloid beta (Aβ) peptide neurobiology. Deficits in DHA or its peroxidation appear to contribute to inflammatory signaling, apoptosis, and neuronal dysfunction in Alzheimer disease (AD).

Studies have used isotopically labeled DHA produced by C. cohnii specifically to investigate these mechanisms: oxidative stress is a commonly observed feature of Alzheimer's disease, and uniformly radiolabeled DHA (biosynthesized in C. cohnii) plays an important role in studying the oxidative fate of DHA in vivo and in vitro.

Evidence strength: Evidence for DHA's neuroprotective and cognitive roles is primarily from basic science (in vitro and animal models) with corroborating epidemiological associations. No clinical trials have tested Crypthecodinium-sourced DHA specifically for Alzheimer's disease or cognitive decline as a distinct primary endpoint.

5.4 Visual Function

Elovanoids are lipid mediators produced in the retinal pigment epithelium by a series of elongation reactions mediated by the fatty acid elongation enzyme ELOVL4. They have antioxidant properties and prevent retinal degeneration by enhancing the expression of pro-survival proteins in cells subjected to uncompensated oxidative stress.

Clinical application of C. cohnii-derived DHA specifically for visual function has been investigated in the context of retinitis pigmentosa. Studies by Hughbanks-Wheaton et al. (2014) and Hoffman et al. (2014; 2015) employed 0.6–3.6 g DHA/person/day (or 30 mg DHA/kg bw/day) of DHA from Crypthecodinium cohnii for 4 years. Transient adverse events were noted in these studies but were not considered severe (e.g., gastrointestinal irritability, blood chemistry alterations). DHA and placebo groups had comparable adverse events, and no severe adverse events requiring hospitalization were reported during the 4-year trial.

Evidence strength: The retinitis pigmentosa studies involved specific, prolonged dosing with C. cohnii-derived DHA, but these studies are primarily noted in the literature in the context of safety evaluation at high doses rather than as demonstration of efficacy. Evidence for visual benefit from DHA in retinal disease at these dose levels remains an area of active research.

5.5 Cardiovascular Health

DHA plays significant roles in enhancing human health and preventing human diseases, such as hypertension, diabetes, and cancers. Docosahexaenoic acid (DHA) is a long-chain ω-3 fatty acid considered essential for human neurodevelopment, cardiovascular health, and immune function. However, the bulk of clinical cardiovascular evidence in the literature is attributed to omega-3 PUFAs generally (typically DHA plus EPA from fish or marine oils) rather than to DHA from Crypthecodinium cohnii specifically. No large-scale randomized controlled trials with cardiovascular endpoints have been conducted using C. cohnii-derived DHA as the sole tested intervention.

Evidence strength: Cardiovascular evidence is indirect. The cardiovascular benefit of omega-3 fatty acids is an active and contested area in clinical research; DHA from C. cohnii specifically lacks dedicated cardiovascular endpoint clinical trials.

6. Body Systems and Health Areas Associated with Crypthecodinium DHA

• Central Nervous System: Structural component of neuronal membranes; role in synaptic signaling, neurogenesis, and neuroinflammation. DHA is the predominant n-3 PUFA within the brain, representing upwards of 40% of total brain PUFA, and many neurophysiological functions have been identified for DHA including mediating the regulation of cell-survival, neuroinflammation, neurogenesis, and participating in signal transduction.
• Visual System (Retina): DHA comprises 60% of the PUFAs in the retina. It supports rhodopsin function and photoreceptor integrity.
• Cardiovascular System: Associated with effects on blood lipids, platelet aggregation, and vascular function as part of the broader omega-3 class of fatty acids.
• Infant Development: Commercially significant for DHA production, notably in infant formulas, given the organism's role as a chloroplast-lacking heterotrophic marine dinoflagellate that can exist in swimming or cyst forms.
• Immune System: DHA is a precursor to specialized pro-resolving mediators (SPMs) including resolvins and protectins involved in resolution of inflammation.

7. Dosage Forms and Dosages Reported in Studies

Dosages of DHA from Crypthecodinium cohnii-derived oils reported in the scientific literature and regulatory dossiers span a wide range depending on the population and application:

• Infant formula (term and preterm infants): DHA added to infant formulas varies from 0.15 to 0.36 wt% of total fatty acids. DHASCO is generally recognized as safe (GRAS) for use in infant formulas at a maximum level of 1.25% (up to 0.5% for DHA alone) of the total dietary fat. A specific clinical study used 17 mg/100 kcal DHA from either Crypthecodinium cohnii or Schizochytrium sp. algae over a 106-day feeding period in healthy term infants from 14 to 120 days of age.
• Dose escalation in adults (bioavailability study): 200, 600, and 1,000 mg DHA per day over 4 weeks, showing a dose-dependent and linear plasma phospholipid DHA response.
• Long-duration high-dose study (retinitis pigmentosa): 0.6–3.6 g DHA per person per day (or 30 mg DHA/kg body weight/day) for up to 4 years.
• Preclinical safety (rats, gavage): A 90-day subchronic toxicity study in rats used doses of 0.5 and 1.25 g/kg body weight/day of DHASCO® oil. In a 90-day rat study, the no-observable-adverse-effect level (NOAEL) for DHA ethyl ester (derived from C. cohnii) was determined at 2500 mg/kg bw/day.
• Developmental toxicity (rodents): Up to 5,000 mg/kg bw/day of algal oil (35% DHA), the highest dose administered by gavage, was determined to be safe in terms of maternal toxicity, embryo/fetal development, and parental reproductive toxicity.

8. Safety Considerations and Known Interactions

8.1 Regulatory Status

DHASCO is generally recognized as safe (GRAS) for use in infant formulas at a maximum level of 1.25% of the total dietary fat (FDA, 2001). In the European Union, Crypthecodinium cohnii was already on the EU market before the Novel Food Regulation came into effect and was therefore not subject to novel food authorization for established uses.

8.2 Toxicological Profile

DHASCO® oil is an algal-derived triglyceride containing 40–50% DHA. Previous studies have shown that DHASCO oil is neither mutagenic nor toxic in acute or 28-day subchronic tests. Animal studies have confirmed the safety of DHASCO.

8.3 Adverse Effects Observed in Clinical Studies

The overall clinical and preclinical safety record for C. cohnii-derived DHA is favorable at typical supplemental doses. Regardless of its source, DHA up to 0.86% of total fatty acids (or 32 mg) was well tolerated. No treatment-related adverse events such as milk allergy, allergy-associated diarrhea, bloody stools, or anaphylaxis were reported. No adverse effects were found on measured outcomes including tolerance, adverse events, growth, anthropometric index, fatty acid composition of the erythrocyte membrane, cognition, and child development in preterm infants.

At higher doses, some transient effects have been documented: in studies employing 0.6–3.6 g DHA/person/day from Crypthecodinium cohnii for 4 years (Hughbanks-Wheaton et al., 2014; Hoffman et al., 2014; 2015), transient adverse events were noted, but were not considered severe (e.g., gastrointestinal irritability, blood chemistry alterations). DHA and placebo groups had comparable adverse events, and no severe adverse events requiring hospitalization were reported in the 4-year trial.

8.4 Extraction Solvent Considerations

The extraction process for C. cohnii oil, as used in infant formulas, typically involves treatment with hexane solvent, acid, and bleach. Following fermentation, hexane extraction, a chemical process, is typically used to extract the oil from the cells. Alternative extraction methods such as supercritical CO₂ have been explored: supercritical fluid extraction runs at temperatures of 313 and 323 K and pressures of 20.0, 25.0, and 30.0 MPa found optimal conditions at 30.0 MPa and 323 K, under which almost 50% of the total oil was extracted after 3 hours with a DHA composition attaining 72% w/w of total fatty acids.

8.5 Considerations Regarding EPA Absence

A distinctive feature relevant to both safety and supplementation practice is the near-total absence of EPA in C. cohnii-derived oil. C. cohnii is one of the most desirable organisms for the production of DHA, and is advantageous because DHA is the only PUFA produced by this organism in appreciable quantities. This means that Crypthecodinium-derived DHA supplements provide DHA without co-administration of EPA, which may be relevant for applications — such as certain infant formula contexts or disease studies — where isolating the effect of DHA alone is desired.

8.6 Comparison with Fish-Oil DHA

A few studies reported no adverse effects of algal DHA from C. cohnii in preterm and term infants. In addition, DHA from other sources such as egg yolk or fish oil also did not show adverse effects in term infants. The data indicate that the source of DHA does not impact the safety of DHA or DHA-oils.

The traditional source of ω-3 fatty acids is fish oil, which contains two major PUFAs, DHA and EPA. However, fish oil as a food additive has significant problems: its strong fishy smell, unpleasant taste, and poor oxidative stability. DHA-oil from C. cohnii is reported to lack the typical fishy smell associated with fish-based DHA sources.

References

• Mendes A, Reis A, Vasconcelos R, Guerra P, Lopes da Silva T (2009). Crypthecodinium cohnii with emphasis on DHA production: a review. Journal of Applied Phycology, 21(2), 199–214. Springer Nature.
• Kwok ACM, Law K, Wong JTY (2023). Oleaginous Heterotrophic Dinoflagellates—Crypthecodiniaceae. Marine Drugs, 21(3), 162. PMC10055936.
• A new synthetic medium for the optimization of docosahexaenoic acid production in Crypthecodinium cohnii. PMC7083267.
• Biosynthesis of uniformly carbon isotope-labeled docosahexaenoic acid in Crypthecodinium cohnii. PMC7065296.
• Growth kinetics, fatty acid composition and metabolic activity changes of Crypthecodinium cohnii under different nitrogen source and concentration. PMC5399014.
• Rewiring the Metabolic Network to Increase Docosahexaenoic Acid Productivity in Crypthecodinium cohnii. Frontiers in Microbiology, 2022. PMC8924677.
• Kim H-Y, Huang BX, Spector AA (2022). Molecular and Signaling Mechanisms for Docosahexaenoic Acid-Derived Neurodevelopment and Neuroprotection. International Journal of Molecular Sciences, 23(9), 4635. PMC9100376.
• Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. PMC9087135.
• Docosahexaenoic Acid and the Aging Brain. PMC2666388.
• Salem N Jr, Litman B, Kim HY, Gawrisch K (2001). Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids, 36(9), 945–59. PubMed 11724467.
• A 3-week dietary bioequivalence study in preweaning farm piglets of two sources of docosahexaenoic acid produced from two different organisms. PubMed 24333867.
• Crypthecodinium cohnii — an overview. ScienceDirect Topics.
• Arterburn LM et al. (2000). A combined subchronic (90-day) toxicity and neurotoxicity study of a single-cell source of docosahexaenoic acid triglyceride (DHASCO® oil). Food and Chemical Toxicology, 38(1), 35–49. ScienceDirect.
• Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs. Food and Chemical Toxicology, 2016. ScienceDirect.
• Safety evaluation of DHA-rich Algal Oil from Schizochytrium sp. Food and Chemical Toxicology, 2011. ScienceDirect.
• U.S. FDA GRAS Notice — DHA-rich oil for infant formula applications (Linyi Youkang Biology). FDA.gov.
• U.S. FDA GRAS Notice No. GRN 000776 (Fermentalg algal oil 35% DHA). FDA.gov.
• U.S. FDA GRAS Notice No. 732 — Docosahexaenoic acid oil produced in Schizochytrium sp. FDA.gov.
• USDA AMS: Docosahexaenoic Acid (DHA) Algal Oil Handling/Processing Technical Report, 2011. USDA.gov.
• Regulating fatty acids in infant formula: critical assessment of U.S. policies and practices. PMC3922793.
• Mehta P et al. (2016). Growth and Tolerability of Healthy Term Infants Fed a New Formula Supplemented with DHA from Schizochytrium sp Microalgae. Journal of Vascular Medicine & Surgery, 4, 267.
• AlgaeBase: Crypthecodinium cohnii (Seligo) Chatton. Guiry MD & Guiry GM (2025). AlgaeBase. World-wide electronic publication, NUI Galway.
• World Register of Marine Species (WoRMS): Crypthecodinium cohnii (Seligo) Javornicky, 1962.
• NCBI Taxonomy Browser: Crypthecodinium cohnii (taxon ID 2866).
• Couto et al. (2010). Supercritical fluid extraction of lipids from the heterotrophic microalga Crypthecodinium cohnii. Engineering in Life Sciences.
• Bioequivalence of Docosahexaenoic Acid from Different Algal Oils in Capsules and in a DHA-Fortified Food. ResearchGate.